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1The rapid growth of the ﬁeld of pharmacoeconom-
ics and outcomes research over the past 15 years
has resulted in many more people dedicating their
careers to the endeavor.
Ours is a rich ﬁeld, incorporating a number of
different research disciplines—pharmacy, econom-
ics, statistics, epidemiology, psychology, medicine,
decision sciences, and operations research—being
practiced in a wide variety of settings. These include
academia, consulting companies, pharmaceutical
companies, managed care organizations, country-
wide regulatory authorities, and consumer organi-
zations. The result is a ﬁeld that is exciting but also
brings the challenges specially associated with a
ﬁeld that encompasses both interdisciplinary and
applied research.
I believe that one of the ways that we can meet
those challenges is by taking seriously the ISPOR
mission of “bridging the gap” in the pages of this
journal. Professional journals generally publish
papers either in a speciﬁc discipline or that are likely
to meet the interests of subscribers who work in a
single setting. Since we are not a discipline-speciﬁc
ﬁeld, Value in Health publishes papers in multiple
disciplines, intended for audiences coming from all
of our diverse settings. How then, do we bridge the
gap? Below is my vision for the journal.
A ﬁrst important role for Value in Health is to
bridge the gap between the different disciplinary
researchers and between the researchers and the
practitioner communities. Universities, consulting
companies, and manufacturers now have thriving
groups of researchers who are generating new
methods as well as applying them to real-world
problems. These researchers have speciﬁc technical
languages that they use to communicate with others
in their same discipline—economist to economist,
psychologist to psychologist, pharmacist to phar-
macist, physician to physician, and statistician to
statistician. These languages allow for efﬁcient 
communication among those in the same discipline.
However, the same technical languages provide
communication barriers for those outside the res-
pective disciplines.
The languages of the research communities
impose special challenges for those of us who work
in an interdisciplinary and multisetting ﬁeld. I
would like Value in Health to lead the way in
meeting such a challenge as follows. When a
researcher develops an innovative methodology for
performing health economic or outcomes research
studies for a new medical interventions (s)he should
write a paper that uses the language of her/his own
discipline sparingly. The researcher should make an
effort in the paper to present the new method in
more generally understood language and to include
a real or simulated example of how this method can
be applied to evaluate new medical interventions. 
In this way, the new methodologic advance would
be accessible to all in our ﬁeld and would also 
meet the approval of the appropriate disciplinary
community.
A second important role for Value in Health is
to bridge the gap between practitioner and practi-
tioner by publishing papers that demonstrate the
use of state-of-the art methods to evaluate medical
interventions in different therapeutic areas. In this
way, a practitioner embarking on a pharmacoeco-
nomic research program for a new product may ﬁnd
ideas and guidance in Value in Health.
A third important role for Value in Health is to
bridge the gap between practitioner and decision
maker. Ours is an applied ﬁeld. Methods develop-
ment and their application to the evaluation of spe-
ciﬁc medical interventions are done for the purpose
of providing information about the value of new
interventions that can help the decision maker who
must determine whether to pay for the intervention
and whether to restrict its use to population sub-
groups. To be helpful, this information must be
based on sound methods and data, must be unbi-
ased, and must be presented in a format that 
the decision maker ﬁnds useful. Several studies in
the 1990s showed that, despite the growth in the
number of drug valuation studies over the past 10
to 20 years, their use by decision makers was low
[1,2]. I would like Value in Health to change this.
In the new century, many countries or health-
care systems are now requiring credible evidence
about the value of new interventions for pricing and
reimbursement negotiations and, thus, use of these
studies is likely to increase. However, these require-
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ments have expanded the scope of the evaluations
from the provision of a cost-effectiveness ratio
alone to provision of:
• Multiple cost-effectiveness ratios;
• Cost consequence analyses (listings of all of the
cost and health and quality of life changes asso-
ciated with the new intervention); and
• Provision of health system impact analyses for
the ﬁrst few years after launch (annual estimates
of budget, health resource, and population
health impacts).
I would like Value in Health to publish papers
that provide the types of information that are useful
to decision makers. To ensure that we do this, in
each issue of the journal, I shall ask decision makers
to comment on the usefulness of our papers to
them. I also encourage you to submit papers that
present the results of studies that are likely to be 
of interest and value to decision makers and that
are presented using measures that are relevant to
them.
I am grateful for the opportunity to serve as
Editor-in-Chief for Value in Health. The journal has
come a long way in its ﬁrst ﬁve years under the lead-
ership of Joel Hay. The MEDLINE listing that we
now have is a measure of all that he accomplished
in a very short time. We have an excellent team of
co-editors and editorial staff and excellent guidance
from our editorial advisory board as well as support
from the ISPOR board and executive staff. We 
also beneﬁt greatly from subscribers such as you
who submit excellent manuscripts upon which the
journal depends for its existence. Please keep them
coming!
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